Fairmount Funds Management LLC
Transaction: 02/09/2026
SELL
Change
-2,904
Price
Not reported
Filing
02/12/2026
Type
SELL
Damora Therapeutics, Inc.
GLTO • Medical - Pharmaceuticals
$21.58
▼ -0.75 (-3.36%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$34.47M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 12.98Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 12, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$21.58
Change-3.36%
Shares Out1.60M
Market Cap$34.47M
Enterprise Value$-497.09M
52W Range2.01 - 38.33
Beta1.60
P/E-0.15
P/B0.07
P/FCF-1.39
EV/EBITDA2.08
EV/FCF19.98
Price$21.58
Change-3.36%
Shares Out1.60M
Market Cap$34.47M
Enterprise Value$-497.09M
52W Range2.01 - 38.33
Beta1.60
P/E-0.15
P/B0.07
P/FCF-1.39
EV/EBITDA2.08
EV/FCF19.98
Earnings Yield-682.01%
FCF Yield-72.19%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio12.98
Quick Ratio12.98
Target$35.25
Target Upside63.35%
Target Median$42.50
Target Range10.00 - 46.00
Volume609.00
Avg Volume224.73K
EPS Surprise-17.00
Investment DNA
How strong this company looks for long-term investors
48
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 12.98Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 5 analyst votes · 2026-09-05
80/100
Bullish
Bullish
3
Hold
2
Bearish
0
Price Target
2026-06-23
Low
$40.00
Mean
$43.67
Median
$45.00
High
$46.00
Insider Transactions
Recent executive and insider activity
Fairmount Funds Management LLC
Transaction: 02/09/2026
BUY
Change
+2,904,000
Price
Not reported
Filing
02/12/2026
Type
BUY
Bruno Julianne
Transaction: 02/09/2026
SELL
Change
-129
Price
Not reported
Filing
02/12/2026
Type
SELL
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC | SELL | -2,904 | Not reported | 02/09/2026 | 02/12/2026 |
| Fairmount Funds Management LLC | BUY | +2,904,000 | Not reported | 02/09/2026 | 02/12/2026 |
| Bruno Julianne | SELL | -129 | Not reported | 02/09/2026 | 02/12/2026 |
| Bruno Julianne | BUY | +129,000 | Not reported | 02/09/2026 | 02/12/2026 |
| Sattarzadeh Sherwin | OTHER | 0 | Not reported | 01/05/2026 | 01/26/2026 |
| Sattarzadeh Sherwin | BUY | +190,376 | Not reported | 01/05/2026 | 01/26/2026 |
| Sattarzadeh Sherwin | BUY | +444,209 | $21.82 | 01/05/2026 | 01/26/2026 |
| Hewes L. Becker | OTHER | 0 | Not reported | 01/05/2026 | 01/07/2026 |
| Hewes L. Becker | BUY | +264,629 | Not reported | 01/05/2026 | 01/07/2026 |
| Hewes L. Becker | BUY | +528,603 | $21.82 | 01/05/2026 | 01/07/2026 |
| Firmani Lori | SELL | -374 | Not reported | 01/02/2026 | 01/06/2026 |
| Firmani Lori | SELL | -135 | $21.41 | 01/02/2026 | 01/06/2026 |
| Winslow Garrett | SELL | -680 | Not reported | 01/02/2026 | 01/06/2026 |
| Winslow Garrett | SELL | -255 | $21.38 | 01/02/2026 | 01/06/2026 |
| Schambye Hans T. | SELL | -1,360 | Not reported | 01/02/2026 | 01/06/2026 |
| Schambye Hans T. | SELL | -700 | $21.38 | 01/02/2026 | 01/06/2026 |
| Bruno Julianne | OTHER | +129,000 | Not reported | 11/10/2025 | 11/17/2025 |
| Bruno Julianne | OTHER | 0 | Not reported | 11/10/2025 | 11/17/2025 |
| CAIN CHRISTOPHER W. | OTHER | 0 | Not reported | 11/10/2025 | 11/17/2025 |
| Fairmount Funds Management LLC | OTHER | +16,366,000 | Not reported | 11/10/2025 | 11/17/2025 |